The business objective of this case study is to provide the client with a comprehensive and actionable technology intelligence report on the GLP-1 disruption reshaping the food and beverage industry — spanning the biology of the GLP-1 pathway, the technology landscape enabling next-generation formulation, the competitive dynamics separating genuine pathway science from marketing claims, and the consumer segmentation driving real product demand. The report equips the client with the knowledge required to move beyond reactive reformulation, assess where its portfolio and partnerships are genuinely exposed or under-leveraged, and identify the white space still available before competitors close it.
BUSINESS OBJECTIVE
Key objectives include:
- Explaining the biological mechanism behind GLP-1 disruption and translating it into direct strategic implications for food and beverage formulation.
- Mapping the technology landscape by Technology Readiness Level, distinguishing commercially proven solutions from early-stage, lower-certainty science.
- Evaluating the competitive landscape by classifying companies according to the strength of their scientific association with the GLP-1 pathway, not their marketing language.
- Segmenting the GLP-1 consumer into three distinct, commercially actionable cohorts to reveal which populations are served today and which remain structurally unaddressed.
- Enabling the client to prioritise reformulation investment, ingredient partnerships, and go-to-market timing ahead of a market still in its early growth phase.
CLIENT’S OBJECTIVE
Identify the technology, competitive, and consumer intelligence capable of revealing where the client’s food and beverage portfolio is exposed or under-leveraged to GLP-1-driven disruption, and where white space remains before competitors close it.
PROJECT BREAKTHROUGHS
Throughout the engagement, we delivered actionable insights by addressing the following:
Why is GLP-1 disruption structural, not cyclical — and which product categories does the pathway biology expose most?
How Will Oral GLP-1s and Patent Expiries Reshape Future Market Growth?
GLP-1 Food Technologies: Proven Solutions vs Emerging Opportunities
Which companies have genuine GLP-1 pathway science — and which are just "GLP-1-friendly" marketing?
Which companies have genuine, evidence-backed GLP-1 pathway science — and which are using "GLP-1-friendly" positioning without it?
RESEARCH METHODOLOGY
The research methodology adopted for this study was designed to ensure comprehensive, multi-dimensional coverage of the GLP-1 technology landscape, competitive dynamics, and consumer behaviour. The approach combined systematic review of primary scientific literature, patent and intellectual property records, regulatory developments, and commercial intelligence inputs, structured across three distinct but interrelated research streams that together form the evidentiary foundation of this report.
Scientific & Clinical Literature Review
- The scientific foundation of this report was built on direct review of the biological mechanism of GLP-1 secretion and signalling, drawing on peer-reviewed literature to establish how specific dietary patterns, ingredients, and engineered molecules interact with the pathway. This stream enabled an evidence-based Technology Readiness Level assessment across core technology categories, from commercially mature solutions such as prebiotics and low-glycaemic carbohydrates to early-stage bioactive peptide platforms, grounded in clinical evidence rather than supplier marketing claims.
Patent & Intellectual Property Verification
- The competitive landscape and patent-to-product mapping were built on direct review of patent records, verifying assignee ownership and grant status directly against primary sources rather than relying on secondary supplier characterisation. This stream was specifically designed to distinguish companies with genuine, company-specific evidence of GLP-1 pathway engagement from those using GLP-1-adjacent language without a verifiable mechanism behind the claim.
Commercial & Market Intelligence Research
- This stream encompassed systematic review of company disclosures, regulatory filings, and industry intelligence from sources including J.P. Morgan Research, Circana, Morgan Stanley, EY-Parthenon, IFF etc. Competitive intelligence was further gathered through trade publications and direct company statements across food, biotechnology, and pharmaceutical sectors.
CHALLENGE & SOLUTION
CHALLENGE 1: THE SCALE OF THE DISRUPTION IS STRUCTURAL, NOT CYCLICAL
For a century, CPG growth models were built on a single principle: sell more. GLP-1 therapies are reshaping consumer appetite, purchasing behaviour, and lifestyle choices at a pace and scale that makes this a permanent shift in food demand, not a temporary dip. With 12.4% of US adults already on GLP-1 therapy and Circana projecting that GLP-1 households will represent 35% of all US food and beverage sales by 2030, the industry is approaching a transformative, once-in-a-generation inflection point that many brands are only beginning to assess.
Solution: Technology Landscape & Maturity Assessment
As a foundational component of this engagement, we conducted a structured Technology Readiness Level assessment across six core technologies enabling GLP-1 food innovation — prebiotics and postbiotics, low-glycaemic carbohydrates, protein enrichment, protein microencapsulation, microbiome-based solutions, and bioactive peptides. Rather than evaluating individual products or brands, this assessment focused on the underlying technologies themselves, since they can be deployed across multiple product categories, licensed to different manufacturers, and scaled over time — providing a more reliable indicator of long-term market potential and investment attractiveness than standalone product launches. This was extended into a patent-to-product mapping, linking proprietary scientific innovations directly to market-facing products to clarify how intellectual property is translating into genuine competitive differentiation.
CHALLENGE 2: THE GLP-1-FRIENDLY VS. GLP-1-ACTIVE GAP
The competitive landscape reveals a clear distinction between GLP-1-friendly nutrition and GLP-1-active innovation. While many established food companies have successfully reformulated products to address the nutritional needs of GLP-1 users, only a small number of organisations possess proprietary technologies capable of directly influencing the GLP-1 pathway itself. Without an evidence-based way to separate genuine pathway science from marketing language, brands risk both misdirected R&D investment and rising regulatory exposure as scrutiny of unstandardised “GLP-1-friendly” claims increases.
Solution: Competitive Landscape & Pathway-Association Mapping
As a second core service, we mapped the GLP-1 food and nutrition landscape across global CPG manufacturers, ingredient suppliers, and emerging startups, classifying each according to the strength of its scientific association with the GLP-1 pathway rather than its marketing positioning. This evidence-based classification distinguished companies with proprietary technologies that directly engage the GLP-1 pathway from those primarily offering nutritional products designed to complement GLP-1 therapies — surfacing that the most advanced pathway-level science is concentrated among a small number of recently founded startups, positioning them as attractive acquisition or licensing targets for established food and beverage players.
CHALLENGE 3: THE SEGMENTATION BLIND SPOT
Nearly all current product development targets a single consumer cohort: the Active User, currently on medication. Circana data shows that 50% of all prior GLP-1 users are likely to use the medication again in the future, creating a large, motivated, and currently underserved ‘Off-Ramp’ population with almost no dedicated products built for it — alongside a far larger Aspirant population of over 100 million US adults seeking GLP-1-like benefits without a prescription. Brands treating the GLP-1 consumer as a single, undifferentiated market are structurally missing the category’s largest open opportunities.
Solution: Consumer Segmentation & Partnership Ecosystem Analysis
Beyond technology and competitive mapping, we developed a three-cohort consumer segmentation model — Active User, Off-Ramp, and Aspirant — sized and profiled by unmet need rather than demographic proxy, with particular focus on the Off-Ramp cohort identified as the category’s largest underserved opportunity. We further analysed the emerging partnership ecosystem reshaping the boundaries between food, biotechnology, and pharmaceutical companies, clarifying how cross-sector collaboration — combining formulation expertise, novel functional ingredients, and clinical and regulatory knowledge — is becoming a key competitive differentiator as the market matures.
OUTCOMES
Clear, evidence-based understanding of which GLP-1 claims are backed by genuine pathway-level science and patent protection, versus which rely on commodity ingredients and unsubstantiated marketing language.
A Technology Readiness Level framework enabling the client to prioritise R&D and partnership investment toward commercially proven technologies while tracking early-stage platforms for future opportunity.
First-mover strategic advantage identified through the Off-Ramp consumer segmentation and the GLP-1-friendly-to-active transition, both currently unaddressed by most competitors.
A decision-ready competitive map and partnership-ecosystem framework identifying which companies to partner with, license from, or monitor.
A clear, risk-aware view of the regulatory exposure created by the current unstandardised “GLP-1-friendly” claims environment, directly informing label and marketing strategy.
A structured short-, medium-, and long-term action plan translating all findings into sequenced, resourced recommendations across portfolio reformulation, ingredient partnerships, and long-term metabolic health platform development.